CHAPTER 1. Industry Overview of Pet Cancer Therapeutics Market
1.1. Definition and Scope
1.1.1. Definition of Pet Cancer Therapeutics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Pet Cancer Therapeutics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Pet Cancer Therapeutics Market By Species
1.2.3. Pet Cancer Therapeutics Market By Medicine Type
1.2.4. Pet Cancer Therapeutics Market By Cancer Type
1.2.5. Pet Cancer Therapeutics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Cancer Type
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Pet Cancer Therapeutics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Pet Cancer Therapeutics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Pet Cancer Therapeutics Market By Species
4.1. Introduction
4.2. Pet Cancer Therapeutics Revenue By Species
4.2.1. Pet Cancer Therapeutics Revenue (USD Million) and Forecast, By Species, 2018-2030
4.2.2. Dogs
4.2.2.1. Dogs Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Cats
4.2.3.1. Cats Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Others
4.2.4.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Pet Cancer Therapeutics Market By Medicine Type
5.1. Introduction
5.2. Pet Cancer Therapeutics Revenue By Medicine Type
5.2.1. Pet Cancer Therapeutics Revenue (USD Million) and Forecast, By Medicine Type, 2018-2030
5.2.2. Vaccines
5.2.2.1. Vaccines Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Chemotherapy Drugs
5.2.3.1. Chemotherapy Drugs Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. Pet Cancer Therapeutics Market By Cancer Type
6.1. Introduction
6.2. Pet Cancer Therapeutics Revenue By Cancer Type
6.2.1. Pet Cancer Therapeutics Revenue (USD Million) and Forecast, By Cancer Type, 2018-2030
6.2.2. Lymphoma
6.2.2.1. Lymphoma Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.3. Melanoma
6.2.3.1. Melanoma Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.4. Mast Cell Cancer
6.2.4.1. Mast Cell Cancer Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.5. Mammary and Squamous Cell Cancer
6.2.5.1. Mammary and Squamous Cell Cancer Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.6. Others
6.2.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 7. North America Pet Cancer Therapeutics Market By Country
7.1. North America Pet Cancer Therapeutics Market Overview
7.2. U.S.
7.2.1. U.S. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
7.2.2. U.S. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
7.2.3. U.S. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
7.3. Canada
7.3.1. Canada Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
7.3.2. Canada Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
7.3.3. Canada Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
7.4. North America PEST Analysis
CHAPTER 8. Europe Pet Cancer Therapeutics Market By Country
8.1. Europe Pet Cancer Therapeutics Market Overview
8.2. U.K.
8.2.1. U.K. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
8.2.2. U.K. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
8.2.3. U.K. Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
8.3. Germany
8.3.1. Germany Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
8.3.2. Germany Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
8.3.3. Germany Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
8.4. France
8.4.1. France Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
8.4.2. France Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
8.4.3. France Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
8.5. Spain
8.5.1. Spain Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
8.5.2. Spain Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
8.5.3. Spain Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
8.6. Rest of Europe
8.6.1. Rest of Europe Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
8.6.2. Rest of Europe Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
8.6.3. Rest of Europe Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Pet Cancer Therapeutics Market By Country
9.1. Asia Pacific Pet Cancer Therapeutics Market Overview
9.2. China
9.2.1. China Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.2.2. China Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.2.3. China Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.3. Japan
9.3.1. Japan Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.3.2. Japan Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.3.3. Japan Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.4. India
9.4.1. India Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.4.2. India Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.4.3. India Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.5. Australia
9.5.1. Australia Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.5.2. Australia Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.5.3. Australia Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.6. South Korea
9.6.1. South Korea Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.6.2. South Korea Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.6.3. South Korea Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
9.7.2. Rest of Asia-Pacific Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
9.7.3. Rest of Asia-Pacific Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Pet Cancer Therapeutics Market By Country
10.1. Latin America Pet Cancer Therapeutics Market Overview
10.2. Brazil
10.2.1. Brazil Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
10.2.2. Brazil Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
10.2.3. Brazil Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
10.3. Mexico
10.3.1. Mexico Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
10.3.2. Mexico Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
10.3.3. Mexico Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
10.4. Rest of Latin America
10.4.1. Rest of Latin America Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
10.4.2. Rest of Latin America Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
10.4.3. Rest of Latin America Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Pet Cancer Therapeutics Market By Country
11.1. Middle East & Africa Pet Cancer Therapeutics Market Overview
11.2. GCC
11.2.1. GCC Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
11.2.2. GCC Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
11.2.3. GCC Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
11.3. South Africa
11.3.1. South Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
11.3.2. South Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
11.3.3. South Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Species, 2018-2030
11.4.2. Rest of Middle East & Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Medicine Type, 2018-2030
11.4.3. Rest of Middle East & Africa Pet Cancer Therapeutics Revenue (USD Million) and Forecast By Cancer Type, 2018-2030
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Pet Cancer Therapeutics Market
12.1. Pet Cancer Therapeutics Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Pet Cancer Therapeutics Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Aratana Therapeutics
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Million), 2021
13.1.3.2. Aratana Therapeutics 2021 Pet Cancer Therapeutics Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Elanco Animal Health
13.3. Vetivax
13.4. Anivive Lifesciences
13.5. Regeneus
13.6. Qbiotics
13.7. Zoetis
13.8. VetDC
13.9. AB Science
13.10. Merial
The estimated value of global pet cancer therapeutics market in 2021 was accounted to be USD 220 Million.
The projected CAGR pet cancer therapeutics market during the analysis period of 2022 to 2030 is 10.4%.
The prominent players of the global pet cancer therapeutics market are Aratana Therapeutics, Elanco Animal Health, Vetivax, Anivive Lifesciences, Regeneus, Qbiotics, Zoetis, VetDC, AB Science, and Merial.
North America held the dominating pet cancer therapeutics market during the analysis period of 2022 to 2030.
Asia-Pacific region exhibited fastest growing CAGR for pet cancer therapeutics market during the analysis period of 2022 to 2030.
Rise in the prevalence of pet cancer and growing awareness of pet diseases among pet owners drives the growth of global pet cancer therapeutics market.
Based on medicine type, chemotherapy drugs output segment is expected to hold the maximum share of the pet cancer therapeutics market.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date